If our Brazil trials don't fill, then you are right.

But if they do, even in an endemic state, there will still be critical patients in need of therapeutics. Supposedly the boosters are wearing off by after 4 months so there will be more of the population getting breakthrough and some of those will go critical. Then there's long haulers.

Also we might get a sort of Philippines status throughout the world of being one of the drugs on the shelf.